Skip to main content

Table 2 CMR, metabolic and clinical parameters before and after aortic valve replacement (AVR) and in healthy controls

From: Circulatory efficiency in patients with severe aortic valve stenosis before and after aortic valve replacement

Parameters

Pre-AVR (n = 41)

Post-AVR (n = 41)

Healthy controls (n = 10)

P value pre-AVR vs post-AVR

P value pre-AVR vs healthy controls

P values post-AVR vs healthy controls

CMR parameters

 Myocardial mass/BSA [mg/m2]

72 ± 21

50 ± 13

40 ± 8

< 0.001

< 0.001

0.019

 LVESD [mm]

34 ± 6

32 ± 4

34 ± 2

< 0.001

0.943

0.035

 Myocardial wall thickness end systolic [mm]

11 ± 2

10 ± 2

8 ± 1

< 0.001

< 0.001

0.001

 LVEDV/BSA [ml/m2]

93 ± 22

77 ± 13

82 ± 9

< 0.001

0.117

0.169

 LVESV/BSA [ml/m2]

41 ± 18

31 ± 9

34 ± 4

< 0.001

0.393

0.064

 LVEF [%]

58 ± 10

61 ± 7

59 ± 3

0.027

0.462

0.088

 LV mass-volume-index [g/ml]

0.8 ± 0.2

0.7 ± 0.2

0.5 ± 0.1

0.001

< 0.001

< 0.001

 RF [%]

9 ± 6

7 ± 5

3 ± 2

0.115

0.004

0.005

 Heart rate [bpm]

67 ± 11

70 ± 12

62 ± 10

0.189

0.302

0.104

 CO_total [l/min]

6.8 ± 1.9

6.3 ± 1.7

5.4 ± 1.2

0.048

0.041

0.184

 CI [(l/min)/m2]

3.5 ± 0.8

3.2 ± 0.7

2.9 ± 0.4

0.056

0.039

0.265

 SV_total [ml]

79 ± 20

76 ± 15

74 ± 19

0.396

0.440

0.440

 ECV midwall [%]

23 ± 2

27 ± 3

 

< 0.001

–

–

 aECV midwall [ml]

32 ± 11

27 ± 9

 

< 0.001

–

–

 aECV/BSA midwall [ml/m2]

16 ± 5

14 ± 4

 

< 0.001

–

–

 GLS [%]

− 21.2 ± 5

− 24.8 ± 4

 

< 0.001

–

–

 Late gadolinium enhancement, n (%)

5 (16%)

8 (23%)

–

1.000

–

–

 Mitral regurgitation II-IV, n (%)

0 (0%)

1 (2%)

0 (0%)

1.000

–

0.618

Heart power parameters

 LV myocardial power [W/m2]

8 ± 3

5 ± 2

5 ± 0.8

< 0.001

< 0.001

0.924

 Circulatory power [W]

1.3 ± 0.4

1.3 ± 0.4

1.1 ± 0.3

0.462

0.097

0.462

 Circulatory efficiency [%]

9.3 ± 3

13.3 ± 5

12.3 ± 2

< 0.001

0.004

0.112

 Circulatory efficiency improvement [%]

–

4.1 ± 5.7

–

–

–

–

Metabolic parameters

 NT-pro-BNP [ng/l]

770 ± 926

334 ± 261

113 ± 113

< 0.001

< 0.001

0.001

 Hemoglobin [g/dl]

14.2 ± 1.3

13.5 ± 1.3

13.9 ± 0.8

0.011

0.607

0.184

 Hematocrit [%]

42 ± 4

42 ± 4

41 ± 3

0.609

0.511

0.497

Clinical parameters

 NYHA III-IV, n(%)

18 (35%)

3 (7%)

0 (0%)

< 0.001

0.009

0.378

 Systolic blood pressure [mmHg]

137 ± 17

138 ± 19

136 ± 15

0.650

0.704

0.877

 Diastolic blood pressure [mmHg]

75 ± 10

75 ± 9

74 ± 9

0.872

0.868

0.831

 Mean arterial pressure [mmHg]

96 ± 11

96 ± 11

95 ± 9

0.948

0.803

0.822

 Mean aortic pressure gradient [mmHg]

56 ± 15

11 ± 5

5 ± 3

< 0.001

< 0.001

< 0.001

 Maximal aortic pressure gradient [mmHg]

83 ± 22

19 ± 7

9.5 ± 5

< 0.001

< 0.001

< 0.001

 Pulse pressure [mmHg]

63 ± 16

63 ± 16

62 ± 13

0.906

0.972

0.905

 6-min walk distance [m]

 

518 ± 84

538 ± 111

–

–

0.646

  1. LVESD, left ventricular end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; RF, regurgitation fraction; HR, heart rate; CO, cardiac output; ECV, extracellular volume; aECV, absolute extracellular volume; GLS, global longitudinal strain; NT-pro-BNP, N terminales pro brain natriuretic peptide; NYHA, New York Heart Association
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us